

Autoimmune Drugs-China Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/AC8D6FCCA9FMEN.html>

Date: April 2018

Pages: 131

Price: US\$ 2,980.00 (Single User License)

ID: AC8D6FCCA9FMEN

Abstracts

Report Summary

Autoimmune Drugs-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Autoimmune Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole China and Regional Market Size of Autoimmune Drugs 2013-2017, and development forecast 2018-2023

Main market players of Autoimmune Drugs in China, with company and product introduction, position in the Autoimmune Drugs market

Market status and development trend of Autoimmune Drugs by types and applications

Cost and profit status of Autoimmune Drugs, and marketing status

Market growth drivers and challenges

The report segments the China Autoimmune Drugs market as:

China Autoimmune Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North China

Northeast China

East China

Central & South China

Southwest China

Northwest China

China Autoimmune Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

TNF Inhibitors

IL Blockers

COX Inhibitors

Phosphodiesterase Type 4 Inhibitors

China Autoimmune Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Clinics

Other

China Autoimmune Drugs Market: Players Segment Analysis (Company and Product introduction, Autoimmune Drugs Sales Volume, Revenue, Price and Gross Margin):

AbbVie

Johnson & Johnson

Biogen

Amgen

Pfizer

F. Hoffmann-La Roche

AstraZeneca

GSK

Merck

Boehringer Ingelheim

Novartis

Sanofi

Takeda Pharmaceuticals

Eli Lilly

Vertex Pharmaceuticals

Eisai

Antares Pharma

UCB (Belgium)

Acorda Therapeutics

Lexicon Pharmaceuticals

KaloBios Pharmaceuticals

Can-Fite BioPharma

Baxter

Daiichi Sankyo
Sandoz

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF AUTOIMMUNE DRUGS

- 1.1 Definition of Autoimmune Drugs in This Report
- 1.2 Commercial Types of Autoimmune Drugs
 - 1.2.1 TNF Inhibitors
 - 1.2.2 IL Blockers
 - 1.2.3 COX Inhibitors
 - 1.2.4 Phosphodiesterase Type 4 Inhibitors
- 1.3 Downstream Application of Autoimmune Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Other
- 1.4 Development History of Autoimmune Drugs
- 1.5 Market Status and Trend of Autoimmune Drugs 2013-2023
 - 1.5.1 China Autoimmune Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Autoimmune Drugs Market Status and Trend 2013-2023

CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Autoimmune Drugs in China 2013-2017
- 2.2 Consumption Market of Autoimmune Drugs in China by Regions
 - 2.2.1 Consumption Volume of Autoimmune Drugs in China by Regions
 - 2.2.2 Revenue of Autoimmune Drugs in China by Regions
- 2.3 Market Analysis of Autoimmune Drugs in China by Regions
 - 2.3.1 Market Analysis of Autoimmune Drugs in North China 2013-2017
 - 2.3.2 Market Analysis of Autoimmune Drugs in Northeast China 2013-2017
 - 2.3.3 Market Analysis of Autoimmune Drugs in East China 2013-2017
 - 2.3.4 Market Analysis of Autoimmune Drugs in Central & South China 2013-2017
 - 2.3.5 Market Analysis of Autoimmune Drugs in Southwest China 2013-2017
 - 2.3.6 Market Analysis of Autoimmune Drugs in Northwest China 2013-2017
- 2.4 Market Development Forecast of Autoimmune Drugs in China 2018-2023
 - 2.4.1 Market Development Forecast of Autoimmune Drugs in China 2018-2023
 - 2.4.2 Market Development Forecast of Autoimmune Drugs by Regions 2018-2023

CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole China Market Status by Types

- 3.1.1 Consumption Volume of Autoimmune Drugs in China by Types
- 3.1.2 Revenue of Autoimmune Drugs in China by Types
- 3.2 China Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in North China
 - 3.2.2 Market Status by Types in Northeast China
 - 3.2.3 Market Status by Types in East China
 - 3.2.4 Market Status by Types in Central & South China
 - 3.2.5 Market Status by Types in Southwest China
 - 3.2.6 Market Status by Types in Northwest China
- 3.3 Market Forecast of Autoimmune Drugs in China by Types

CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Autoimmune Drugs in China by Downstream Industry
- 4.2 Demand Volume of Autoimmune Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Autoimmune Drugs by Downstream Industry in North China
 - 4.2.2 Demand Volume of Autoimmune Drugs by Downstream Industry in Northeast China
 - 4.2.3 Demand Volume of Autoimmune Drugs by Downstream Industry in East China
 - 4.2.4 Demand Volume of Autoimmune Drugs by Downstream Industry in Central & South China
 - 4.2.5 Demand Volume of Autoimmune Drugs by Downstream Industry in Southwest China
 - 4.2.6 Demand Volume of Autoimmune Drugs by Downstream Industry in Northwest China
- 4.3 Market Forecast of Autoimmune Drugs in China by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AUTOIMMUNE DRUGS

- 5.1 China Economy Situation and Trend Overview
- 5.2 Autoimmune Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 AUTOIMMUNE DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA

- 6.1 Sales Volume of Autoimmune Drugs in China by Major Players
- 6.2 Revenue of Autoimmune Drugs in China by Major Players
- 6.3 Basic Information of Autoimmune Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Autoimmune Drugs Major Players

6.3.2 Employees and Revenue Level of Autoimmune Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 AUTOIMMUNE DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AbbVie

7.1.1 Company profile

7.1.2 Representative Autoimmune Drugs Product

7.1.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of AbbVie

7.2 Johnson & Johnson

7.2.1 Company profile

7.2.2 Representative Autoimmune Drugs Product

7.2.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.3 Biogen

7.3.1 Company profile

7.3.2 Representative Autoimmune Drugs Product

7.3.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Biogen

7.4 Amgen

7.4.1 Company profile

7.4.2 Representative Autoimmune Drugs Product

7.4.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Amgen

7.5 Pfizer

7.5.1 Company profile

7.5.2 Representative Autoimmune Drugs Product

7.5.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Pfizer

7.6 F. Hoffmann-La Roche

7.6.1 Company profile

7.6.2 Representative Autoimmune Drugs Product

7.6.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche

7.7 AstraZeneca

7.7.1 Company profile

- 7.7.2 Representative Autoimmune Drugs Product
- 7.7.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.8 GSK
 - 7.8.1 Company profile
 - 7.8.2 Representative Autoimmune Drugs Product
 - 7.8.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of GSK
- 7.9 Merck
 - 7.9.1 Company profile
 - 7.9.2 Representative Autoimmune Drugs Product
 - 7.9.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Merck
- 7.10 Boehringer Ingelheim
 - 7.10.1 Company profile
 - 7.10.2 Representative Autoimmune Drugs Product
 - 7.10.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 7.11 Novartis
 - 7.11.1 Company profile
 - 7.11.2 Representative Autoimmune Drugs Product
 - 7.11.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.12 Sanofi
 - 7.12.1 Company profile
 - 7.12.2 Representative Autoimmune Drugs Product
 - 7.12.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 7.13 Takeda Pharmaceuticals
 - 7.13.1 Company profile
 - 7.13.2 Representative Autoimmune Drugs Product
 - 7.13.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
- 7.14 Eli Lilly
 - 7.14.1 Company profile
 - 7.14.2 Representative Autoimmune Drugs Product
 - 7.14.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.15 Vertex Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Autoimmune Drugs Product
 - 7.15.3 Autoimmune Drugs Sales, Revenue, Price and Gross Margin of Vertex Pharmaceuticals
- 7.16 Eisai
- 7.17 Antares Pharma

- 7.18 UCB (Belgium)
- 7.19 Acorda Therapeutics
- 7.20 Lexicon Pharmaceuticals
- 7.21 KaloBios Pharmaceuticals
- 7.22 Can-Fite BioPharma
- 7.23 Baxter
- 7.24 Daiichi Sankyo
- 7.25 Sandoz

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOIMMUNE DRUGS

- 8.1 Industry Chain of Autoimmune Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AUTOIMMUNE DRUGS

- 9.1 Cost Structure Analysis of Autoimmune Drugs
- 9.2 Raw Materials Cost Analysis of Autoimmune Drugs
- 9.3 Labor Cost Analysis of Autoimmune Drugs
- 9.4 Manufacturing Expenses Analysis of Autoimmune Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF AUTOIMMUNE DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Autoimmune Drugs-China Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/AC8D6FCCA9FMEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC8D6FCCA9FMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970